<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098033</url>
  </required_header>
  <id_info>
    <org_study_id>2127</org_study_id>
    <nct_id>NCT00098033</nct_id>
  </id_info>
  <brief_title>Investigation of Clofarabine in Acute Leukemias</brief_title>
  <official_title>Phase II Clinical and Pharmacodynamic Investigation of Clofarabine in Acute Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      The goals and objectives of this project are to evaluate the antileukemic activity of the
      investigational agent clofarabine in patients with acute myelogenous leukemia (AML), acute
      lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) in accelerated and blastic
      phases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of the project are (1) conduct the phase II study of clofarabine and
      evaluate the antileukemic efficacy in AML, ALL, and CML-accelerated and blastic phases in
      terms of complete response (CR) rate, response duration, and survival; and (2) analyze the
      relationship between cellular uptake and retention of clofarabine triphosphate (the active
      metabolite), inhibition of DNA synthesis, and clinical outcome.

      Completion date provided represents the completion date of the grant per OOPD records
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>64</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patient is diagnosed with AML, ALL, myelodysplastic syndrome (MDS), and CML in
             transformation (includes CML-blastic phase and CML-accelerated phase).

          -  No prior chemo-, immuno-, or radio-therapy for 2 weeks before entering the study,
             unless progressive life-threatening leukemia as judged by the treated physician.

          -  Adequate liver function (bilirubin &lt;/= 2 mg%) and renal function (creatinine &lt;/= 2
             mg%).

          -  Pregnant and lactating females not eligible.

          -  Zubrod performance status 0-2

          -  Adequate cardiac status

          -  No life-threatening conditions (e.g. infections) which may cause death within 3 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop M Kantarjian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge E Cortes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <link>
    <url>http://www.clinicaltrials.gov</url>
    <description>FDA's clinical trials website</description>
  </link>
  <reference>
    <citation>Cortes JE, Gandhi V, et al. Clofarabine (2-chloro-9-(deoxy-2-fluoro-b-D-arabinosfuranosyl)adenine) is active for patients with refractory or relapsed acute leukemia. #739 ASH 2002.</citation>
  </reference>
  <verification_date>December 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2004</study_first_submitted>
  <study_first_submitted_qc>December 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2004</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>clinical</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>investigational drug clofarabine</keyword>
  <keyword>AML, ALL, CML-accelerated phase, CML-blastic phase</keyword>
  <keyword>Chronic Myelogenous Leukemia - accelerated phase</keyword>
  <keyword>Chronic Myelogenous Leukemia - blastic phase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

